Lilly is engaging in dialogue with government and regulatory authorities to donate bamlanivimab and etesevimab to speed up access and provide treatment options for patients with COVID-19, says the company
Eli Lilly ties up with MSN Labs, Torrent Pharma for sale of Covid-19 drug Baricitnib in India
Baricitinib has received restricted emergency use approval from the health ministry s central drugs standard control organisation for use in combination with Remdesivir for treatment of suspected or confirmed COVID-19 patients
BusinessToday.In | May 13, 2021 | Updated 12:33 IST
Lilly is engaged in active dialogue with regulatory authorities and government to donate anti-COVID-19 treatments
Eli Lilly has signed additional voluntary licences with MSN Labs and Torrent Pharma for manufacturing and sale of Covid-19 drug Baricitnib in India. The pacts with these two companies have been signed after US-based Lilly entered into an agreement with five homegrown pharma companies.
Story
Dr Reddy s to make, sell Eli Lilly s COVID-19 drug Baricitinib in India; 5th drugmaker to do so
Dr Reddy s has also tied up with Russian Direct Investment Fund, Russia s sovereign wealth fund that has bankrolled Sputnik V. It has also collaborated with DRDO to develop an anti-Covid drug, 2-deoxy-D-glucose (2-DG), which has also received approval from DCGI
BusinessToday.In | May 12, 2021 | Updated 11:31 IST
Baricitinib has received restricted emergency use approval from the health ministry s central drugs standard control organisation
Dr Reddy s Laboratories has entered into a royalty-free, non-exclusive voluntary licencing agreement with US-based pharma major Eli Lilly and Company for the manufacture and sale of the drug, Baricitinib. Baricitinib has received restricted emergency use approval from the health ministry s central drugs standard control organisation for use in combination with Remdesivir for treatment of suspected or confirmed COVID-19 patients who requir